Table 1.
Patient baseline characteristics
| Group | Total | Thermal (N = 23) | PFA (N = 18) | P-value |
|---|---|---|---|---|
| Demographics | ||||
| Age (years) | 58 ± 9 | 59 ± 9 | 58 ± 9 | 0.87 |
| Male gender | 32 (78%) | 17 (74%) | 15 (83%) | 0.78 |
| Clinical status and history | ||||
| LVEF (%) | 61 ± 7 | 61 ± 8 | 62 ± 6 | 0.44 |
| Hypertension | 8 (20%) | 4 (17%) | 4 (22%) | 0.71 |
| Diabetes | 1 (2%) | 0 (0%) | 1 (6%) | 0.26 |
| Smoking | 17 (41%) | 9 (39%) | 8 (44%) | 0.74 |
| Dyslipidaemia | 7 (17%) | 4 (17%) | 3 (17%) | 0.95 |
| Obesity | 5 (12%) | 1 (4%) | 4 (22%) | 0.09 |
| Stroke or TIA | 3 (7%) | 1 (4%) | 2 (11%) | 0.54 |
| CAD | 3 (7%) | 2 (9%) | 1 (6%) | 0.71 |
| Medication | ||||
| Warfarin | 2 (5%) | 2 (9%) | 0 (0%) | 0.21 |
| NOAC | 39 (95%) | 21 (91%) | 18 (100%) | 0.21 |
| AAD class I | 16 (39%) | 7 (30%) | 9 (50%) | 0.21 |
| AAD class II | 17 (41%) | 9 (39%) | 8 (44%) | 0.74 |
| AAD class III | 15 (36%) | 10 (43%) | 5 (28%) | 0.31 |
| No AAD | 10 (24%) | 6 (26%) | 4 (22%) | 0.78 |
AAD, anti-arrhythmic drug; CAD, coronary artery disease; LVEF, left ventricular ejection fraction; NOAC, novel oral anticoagulant; PFA, pulsed field ablation; TIA, transient ischaemic attack.